Abstract:Objective To investigate whether dendritic cells(DCs)pulsed with mutant K-ras peptide(12-Val)can induce efficiently specific anti-tumor immune response aganist pancreatic cancer.Methods Immature DCs were isolated from the pefipheral blood of a volunteer and were pulsed with synthesized mutant K-ras peptide(YKLVVVGAV).When the DCs were matured the expression rate of Kras antigen epitope on the DC's surface was detected by monoantibody(K-ras-12-Val).Autogeneic and homologous T cells were mixed with the mutant K-ras peptide-pulsed DCs.Human pancreatic cancer cells of the line Patu8988 were mixed with cytotoxic T lymphocytes(CTLs)cultured for 5 days.and the killing eriects of the CTLs on the ceils was assessed by MTY method.Patu8988 cells were iniected subcutaneously into nude mice.cancer cells were obtained from the tumor masses and injected subcutaneously into other nude mice to establish mice models of pancreatic cancer.Then 32 mice with pancreatic cancer were randomly divided into 4 equal groups:control group.K-ras specific CTL intra-tumor injection group,CTL caudal vein injection group,and IL-2 activated non-specific CTL intra-tumor injection group.The tumor size was measure regularly.Immunohistochemistry was used to detect the pathological analysis of the transplanted tumors.Results The mutational epitope(K-ras-12-Val)induced by mutant peptide could be foand on the DCs' suIface efficiently.After co-incubation with the mature DCs pulsed with tumor antigen the autogeneic T cells were activated.the CD8+T cells accounted for(44.8±2.1)%.Without damage the normaI tissue cells,the killing rate of activated K-ras specific CTLs to the tumor cell when Lhe ratios of CTL:Patu8988 cells were 10:1,20:1,and 50:1 were(21.2±1.9)%,(32.4±2.1)%,and(45.7±5.3)% respectively.alJ while the killing efficiency significantly superior to those of the non-specific activated Tlymphocyte(all P<0.05).Eight days after CTL iniection into the nude mice the tumor size of the intratumor injection group was(68±13)mm3,significantly smaller than those of the control group and IL-2 activated non-specific CTL intra-tumor injection group[(87±14)mm3 and(79±19)mm3,both P<0.05].The survival rates of the nude mice of the K-ras specific CTL intra-tumor injection group,CTL caudal vein injection group.and IL-2 activated non-specific CTL intra-tumor injection group were all significantly higher than that of the contml group(all P<0.05),and the survival rate ofthe K-ras specific CTL intra-tumor injection group was significantly higher than that of the IL-2 activated non-specific CTL intra.tumor injection group(P<0.05).Immunohistochemieal staining confirmed that K-ras specific CTL had the ability to move toward tumor.Conclusion DCs pulsed with mutant K-ras peptide(12-Val)induces specific anti-tumor immune response in pancreatic cancer efficiently.

Anti-tumor Effects of Dendritic Cell Vaccine Pulsed with Rat Pancreatic Cancer Cell Lysate on Rat Pancreatic Cancer

Anti-tumor Immunity with Dendritic Cells ( DC) Vaccine Modified by IL-18

The Immunotherapeutic Effect of Dendritic Cells Vaccine Modified with Interleukin-18 Gene and Tumor Cell Lysate on Mice with Pancreatic Carcinoma

Prophylactic Dendritic Cell Vaccination Controls Pancreatic Cancer Growth in a Mouse Model.

Dendritic Cell Immunotherapy Induces Anti-Tumor Effect in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma.

Immunotherapeutic efficacy of transforming growth factor-beta insensitive dendritic cell vaccine in mice with renal carcinoma

Anti-tumor Activity of Dendritic Cells Loading in Situ Tumor Lysate Antigen Proudced by Radiofrequency Ablation

In Vivo Anti-Tumor Response Induced by Dendritic Cell Vaccine Modified by Mutant K-Ras Genes

Immunotherapy of mouse renal cell carcinoma with tumor lysate-pulsed dendritic cells

Anti-tumor Response of Dendritic Cells after Pulsed with Whole Tumor Cell Lysates of Prostate Cancer Cell Line

Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models

The anti-tumor immune response of specific cytotoxic T lymphocytes induced by breast cancer stem cells RNA-DCs vaccine

Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide

CD80mAb enhanced immature dendritic cells induces donor-specific immune tolerance in an allograft rat pancreaticoduodenal transplantation model

Anti-tumor effects of tumor cell vaccine by epigenetic modification on pancreatic cancer of hamster

[Controlled Live Dendritic Cell Vaccine Mediates Potent Antitumor Immune Responses].

Effect cytotoxic T lymphocyte associated antigen-4 immunoglobulin gene transfer to the same donor dendritic cells on rat pancreatic islet allografts

Experimental Study of Treatment of Prostate Cancer with Murine Dendritic Cells Pulsed with Tumor Cell RNA

Dendritic Cells Vaccines Activated by Combined Toll-like Receptor Llgands Inhibit Murine Colon Cancer in Vivo

Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes

Immunological response in rats: with combinative treatment of heat-shocked antigen-pulsed dendritic cell and radiofrequency ablation